MRDTECT
LIVE

Serial Number

97225171

Owner

Pillar Biosciences, Inc.

Attorney

Andrew T. Pettit

Filing Date

Jan 18, 2022

Add to watchlist:

No watchlists yet
View on USPTO

MRDTECT Trademark

Serial Number: 97225171

MRDTECT is a trademark filed by Pillar Biosciences, Inc. on January 18, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Pillar Biosciences, Inc. (17 trademarks)

Natick, MA 01760

Entity Type: 03

Trademark Details

Filing Date

January 18, 2022

Registration Date

Not Registered

Published for Opposition

June 13, 2023

Goods & Services

Data processing services for medical, clinical, and scientific purposes; data processing services, namely, analysis of sequencing data to detect the presence and prevalence of cancer molecules; management services, namely, management of business information insights learned through analysis of the information relating to preventative medicine marketability

Reagents and reagent kits comprising nucleic acids, naturally occurring nucleotides, modified nucleotides, enzymes, and buffers, all for the purpose of preparing, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, regulations, transcriptions, and expressions, with the aforementioned reagents and reagent kits being in the fields of scientific research, clinical research, and diagnostic research; biological and biochemical reagents and reagent kits comprising nucleic acids, naturally occurring nucleotides, modified nucleotides, enzymes, and buffers, for selectively amplifying nucleic acid fragments for scientific research, clinical research, and diagnostic research; biological and biochemical kits for scientific research, clinical research, and diagnostic research; reagents, assays, enzymes, nucleotides, buffers, and chemical and biological preparations for diagnostic purposes; reagents and reagent kits comprising nucleic acids, naturally occurring nucleotides, modified nucleotides, enzymes, and buffers, for scientific, clinical, and research use in connection with amplifying, analyzing, labeling, and detecting nucleic acids; reagents and reagent kits comprising nucleic acids, naturally occurring nucleotides, modified nucleotides, enzymes, and buffers, for scientific, clinical, and research use in connection with monitoring the efficacy of therapies through analysis of bodily fluids; reagents and reagent kits comprising nucleic acids, naturally occurring nucleotides, modified nucleotides, enzymes, and buffers, for scientific, clinical, and research use in connection with determining the presence of diseases through analysis of bodily fluids; reagents and reagent kits comprising nucleic acids, naturally occurring nucleotides, modified nucleotides, enzymes, and buffers, for scientific, clinical, and research use in connection with monitoring therapeutic response and the recurrence of diseases through analysis of bodily fluids; reagents and reagent kits comprising nucleic acids, naturally occurring nucleotides, modified nucleotides, enzymes, and buffers, for scientific, clinical, and research use in connection with detecting cancer molecules in bodily fluids

Providing biological sample testing services for others in the field of medical diagnostics; providing biological sample testing services for others for medical purposes, namely, for the diagnosis and treatment of cancer; providing reagent sample testing and diagnostic services for others, namely, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the field of diagnostics; genetic testing for medical purposes; medical testing for diagnostic and treatment purposes; consulting services for medical purposes, health and wellness assessment services; providing health and wellness information; medical services, namely, diagnostic testing for the presence of cancer molecules in bodily fluids; diagnostic testing relating to human health; medical testing services relating to the diagnosis, treatment, and recurrence monitoring of disease; management services, namely, management of medical information derived through nucleic acid sequencing, including next-generation sequencing (NGS), and information gathered through analysis of the medical information

Reagents and reagent kits comprising nucleic acids, naturally occurring nucleotides, modified nucleotides, enzymes, and buffers, all for the purpose of preparing, detecting, sequencing, and analyzing nucleic acids, genes, genomes, nucleotide sequence variants and modifications, regulations, transcriptions, and expressions, with the aforementioned reagents and reagent kits being used for medical and veterinary purposes; biological and biochemical reagents and reagent kits for selectively amplifying nucleic acid fragments for medical and veterinary purposes; biological and biochemical kits for medical and veterinary diagnostic purposes; reagents, assays, enzymes, nucleotides, buffers, and chemical and biological preparations for diagnostic purposes; reagents and reagent kits for amplifying, analyzing, labeling, and detecting nucleic acids for medical and veterinary purposes; reagents and reagent kits for monitoring the efficacy of therapies through analysis of bodily fluids for medical and veterinary purposes; reagents and reagent kits for determining the presence of diseases through analysis of bodily fluids for medical and veterinary purposes; reagents and reagent kits for monitoring therapeutic response and the recurrence of diseases through analysis of bodily fluids for medical and veterinary purposes; reagents and reagent kits detecting cancer molecules in bodily fluids for medical and veterinary purposes; diagnostic substances for medical and veterinary use

Software as a service (SaaS), namely, hosting non-downloadable software for use by others for collecting, managing, and analyzing data in the fields of scientific research, clinical research, diagnostic research, and diagnostics; software as a service (SaaS), namely, hosting non-downloadable software for use by others for analyzing biological samples; software as a service (SaaS), namely, hosting non-downloadable software for use by others for analyzing biological samples for medical purposes, namely, for the diagnosis and treatment of cancer; software as a service (SaaS), namely, hosting non-downloadable software for use by others with reagents and reagent kits, all for the purpose of detecting, sequencing, and analyzing nucleic acids, , genes, genomes, nucleotide sequence variants and modifications, all in the fields of scientific research, clinical research, diagnostic research, and diagnostics; software as a service (SaaS), namely, hosting non-downloadable software for use by others for bioinformatics and gene expression microarray image analysis, namely, gene expression quantification, gene image processing, and gene information processing; software as a service (SaaS), namely, hosting non-downloadable software for health and wellness assessment, namely, for genomic analysis; software as a service (SaaS), namely, hosting non-downloadable software for genetic and bioinformatics analysis; bioinformatics services, namely, product research and development in the field of bioinformatics; data processing services for medical, clinical, and scientific purposes; developing diagnostic testing models for others for medical, clinical, and scientific purposes; genetic testing for scientific research purposes; scientific consulting relating to scientific research; scientific services, namely, detection and analysis of cancer molecules in bodily fluids; scientific, clinical, and diagnostic research in the field of bioinformatics; scientific, clinical, and diagnostic research in the fields of disease detection and management; scientific, clinical, and diagnostic research in the fields of cancer discovery, cancer management, therapy efficacy, and recurrence monitoring

Downloadable software for the collection, management, and analysis of data for use in the fields of scientific research, clinical research, diagnostic research, and diagnostics; downloadable software for analyzing biological samples; downloadable software for analyzing biological samples for medical purposes, namely, for the diagnosis and treatment of cancer; downloadable software for use with reagents and reagent kits, all for the purpose of detecting, sequencing, and analyzing nucleic acids, genes, genomes, nucleotide sequence variants and modifications, all in the fields of scientific research, clinical research, diagnostic research, and diagnostics; downloadable software for bioinformatics and gene expression microarray image analysis, namely, gene expression quantification, gene image processing, and gene information processing; downloadable software for health and wellness assessment, namely, for use in genomic analysis; downloadable software for genetic and bioinformatics analysis; downloadable software for testing deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) molecules for research purposes; downloadable software for testing DNA and RNA molecules for diagnostic purposes; downloadable software, namely, data analysis software for use in the fields of nucleic acid sequencing, genotyping, scientific research, clinical research, diagnostics research, and diagnostics; downloadable software for bioinformatics analysis of information derived through next generation sequencing (NGS); downloadable software for discovering and tracking indicators of disease through analysis of sequencing data; downloadable software for detecting the presence and prevalence of cancer molecules through analysis of sequencing data; universal serial bus (USB) flash drives, memory cards, and solid state drives with software installed thereon, namely, software for genetic and bioinformatics analysis; electronic devices, namely, tablet computers, desktop computers, and mobile workstations, with software installed thereon, namely, software for genetic and bioinformatics

Filing History

SOU TEAS EXTENSION RECEIVED
Jan 15, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 1, 2025 EXRA
SOU EXTENSION 4 GRANTED
Aug 1, 2025 EX4G
SOU EXTENSION 4 FILED
Jul 31, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Jul 31, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 3, 2025 EXRA
SOU EXTENSION 3 GRANTED
Jan 13, 2025 EX3G
SOU EXTENSION 3 FILED
Jan 13, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Jan 13, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 30, 2024 EXRA
SOU EXTENSION 2 GRANTED
Jul 30, 2024 EX2G
SOU EXTENSION 2 FILED
Jul 30, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Jul 30, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 3, 2024 EXRA
SOU EXTENSION 1 GRANTED
Feb 1, 2024 EX1G
SOU EXTENSION 1 FILED
Feb 1, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 1, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 8, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 13, 2023 NPUB
PUBLISHED FOR OPPOSITION
Jun 13, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 24, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 8, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 5, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 5, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 5, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 9, 2022 GNRN
NON-FINAL ACTION E-MAILED
Nov 9, 2022 GNRT
NON-FINAL ACTION WRITTEN
Nov 9, 2022 CNRT
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 7, 2022 GNRN
NON-FINAL ACTION E-MAILED
Nov 7, 2022 GNRT
NON-FINAL ACTION WRITTEN
Nov 7, 2022 CNRT
ASSIGNED TO EXAMINER
Oct 26, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 24, 2022 NWOS
NEW APPLICATION ENTERED
Jan 21, 2022 NWAP